welcome
CNBC

CNBC

Health

Health

Novo Nordisk shares pop 9% on early-stage weight loss drug trial results

CNBC
Summary
Nutrition label

82% Informative

Danish pharmaceutical giant Novo Nordisk reported positive early-stage results for its amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks .

Novo said the most adverse effects of the treatment were gastrointestinal, with the vast majority being "mild to moderate in severity".

VR Score

85

Informative language

87

Neutral language

60

Article tone

formal

Language

English

Language complexity

61

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

1

Affiliate links

no affiliate links